Condition: Osteoporosis · Osteoporosis, Steroid Induced · Inflammatory Rheumatism · Sponsor: Diakonhjemmet Hospital
Bone turnover markers (BTMs) are recommended as an important tool in follow-up of osteoporosis treatment. However, there is a lack of knowledge in the reliability of BTMs during and after glucocorticoid treatment. Glucocorticoids suppresses BTMs during treatment with at least 30% and, moreover, glucocorticoids increase the risk of fractures. Patients with an inflammatory joint disease are at increased risk of osteoporosis, and disease flares are often treated with glucocorticoids, which in turn can lead to loss in reliability of the BTMs in patients who also are on osteoporosis treatment. There is a need of more knowledge on BTM changes during and after glucocorticoid treatment for optimized patientcare, reduced risk of side effects and reduced health economic costs.
This description comes directly from the study's public registry record.
Birgitte Nellemann Nellemann, MD PHD · +4747957020 · birgittenellemann@gmail.com
Tove T Borgen, MD PHD · +4795933386 · tove.tveitan.borgen@vestreviken.no
Always discuss trial participation with your own doctor first.
| Vestre Viken HF, Drammen | Drammen, Norway | Recruiting |
| Diakonhjemmet hospital | Oslo, Norway | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06395883